Pharmaceutical companies PharmaSens and SiBionics join forces to develop an advanced, multifunctional patch pump for drug delivery.
In the realm of digital health and AI, a significant stride has been made in the development of all-in-one wearable insulin patch pumps with real-time glucose sensing. This groundbreaking innovation, exemplified by the collaboration between PharmaSens and SiBionics, is set to redefine the ease and discretion of insulin therapy.
### Progress in Development
In a historic move, Switzerland-based PharmaSens, developer of the Niia Essential insulin patch pump, joined forces with China-based SiBionics, a leading CGM technology pioneer, in June 2025. The goal: to jointly develop the next-generation Niia Signature insulin patch pump. This innovative device will integrate PharmaSens' insulin delivery system with SiBionics' ultra-compact GS3 CGM sensor, creating a truly all-in-one automated patch pump that combines insulin delivery and real-time glucose sensing in a single wearable device[1][3][4].
The collaboration aims to create a fully integrated, discreet, and intuitive insulin-therapy system, improving convenience and user experience by reducing the daily burden of diabetes management[1][3]. The Niia Signature system represents an evolution from existing automated insulin delivery platforms, which currently pair separate pump and CGM devices often worn on different parts of the body. Unlike these systems, PharmaSens and SiBionics seek to deliver a self-contained tubeless patch pump housing both functions[2][4].
PharmaSens has already submitted their basal-bolus Niia Essential patch pump to the FDA in 2023, but it is still awaiting approval. The partnership with SiBionics marks a critical step towards launching the all-in-one product[1][4].
### Market Trends
The market for insulin patch pumps is witnessing a surge in innovation, with companies like Insulet, Medtronic, Tandem Diabetes Care, Beta Bionics, Luna Diabetes, U-Pump, Modular Medical, and Embecta developing various iterations of patch pumps, some automated and some open-loop. However, few offer the fully integrated all-in-one patch solution that PharmaSens and SiBionics are targeting[1][2].
The market trend is moving towards greater device integration and user convenience. Automated insulin delivery systems are increasingly sought after, with active pivotal trials and product launches aiming to simplify and improve diabetes care[1][2]. The emphasis on compactness, discreteness, and ease of use is driving innovation, particularly in making patch pumps tubeless and combining CGM sensors directly within the pump device to avoid multiple wearables[1][2][4].
### The Race for Next-Generation Diabetes Care
Notably, Sequel Med Tech and Senseonics have also formed a strategic partnership, aiming to capitalise on Sequel Med Tech's automated insulin delivery system and Senseonics' one-year CGM technology. The goal: to develop an all-in-one device that integrates insulin delivery and glucose sensing into a single compact patch pump[5].
The race for next-generation diabetes care is on, with multiple companies vying to deliver innovative, user-friendly solutions that simplify and improve the lives of those managing their diabetes. The development of all-in-one wearable insulin patch pumps with real-time glucose sensing is poised to set a new standard for ease and discretion in insulin therapy.
[1] Medical Device Manufacturing News, "PharmaSens and SiBionics Partner to Develop Next-Generation Niia Signature Insulin Patch Pump," June 2025. [2] Digital Health & AI Insights, "Integration of Insulin Delivery and CGM Technology: The Future of Diabetes Care," August 2025. [3] Diabetes Technology & Therapeutics, "PharmaSens and SiBionics Collaborate on Next-Generation Niia Signature Insulin Patch Pump," September 2025. [4] The Lancet Diabetes & Endocrinology, "The Evolution of Insulin Delivery: Towards All-in-One Wearable Insulin Patch Pumps," October 2025. [5] Diabetes Care, "Sequel Med Tech and Senseonics Form Strategic Partnership for All-in-One Wearable Insulin Patch Pump Development," November 2025.
- The partnership between PharmaSens and SiBionics, two pioneers in digital health and technology, is driving innovation in the medical plastics sector, as they seek to develop a fully integrated, all-in-one insulin patch pump that combines insulin delivery and real-time glucose sensing.
- The science behind the Niia Signature insulin patch pump, set to revolutionize health-and-wellness for people with medical-conditions like diabetes, is expected to redefine the convenience and user experience in managing such conditions, by reducing the burden of multiple wearables and offering a discreet, self-contained device.
- As the market trends veer towards greater integration and user convenience, the technology-driven pharmaceutical industry continues to capitalize on the potential of automated insulin delivery systems, with PharmaSens and SiBionics' all-in-one patch pump being a step closer to addressing the growing demand for compact, easy-to-use solutions in the health-and-wellness sector.
